Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.35 |
| ▸ | FADS1 | O60427 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.32 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23415181 | 0.81 | USP7 (0.34) | FADS1AKT1AKT2CYP11B1CYP11B2 | |
| SCHEMBL23456485 | 0.79 | FADS1 (0.51) | FADS1CYP11B1CYP11B2 | |
| SCHEMBL23414873 | 0.78 | ALDH1A1 (0.34) | SLC2A1FADS1 | |
| SCHEMBL23414877 | 0.78 | FADS1 (0.52) | FADS1 | |
| SCHEMBL23414973 | 0.78 | FADS1 (0.52) | SLC2A1FADS1 | |
| SCHEMBL23415032 | 0.76 | FADS1 (0.38) | FADS1 | |
| SCHEMBL23414842 | 0.75 | ALPG (0.40) | FADS1 | |
| SCHEMBL23456476 | 0.75 | RXFP1 (0.40) | FADS1CYP11B1CYP11B2 | |
| SCHEMBL23414718 | 0.73 | METTL3 (0.39) | AKT1AKT2MCHR1CYP11B1CYP11B2 | |
| SCHEMBL23456454 | 0.73 | FADS1 (0.36) | FADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4065579-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | SLC2A1 3374/4885FADS1 5/4885AKT1 1416/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | SLC2A1 3374/4885FADS1 5/4885AKT1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.